Rhonda Farnum
Fortuna: 4 M $ al 31/05/2026
Fortuna: 4 M $ al 31/05/2026
Rhonda F.
Farnum is currently Chief Business Officer & SVP-Medical Affairs at Theravance Biopharma, Inc., a position held since 2021, with employment at the firm starting in 2018.
Formerly, Ms. Farnum was Head of the Hematology Business Unit at Onyx Pharmaceuticals, Inc. from 2014 to 2015.
Education includes undergraduate studies at the University of Georgia.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
THERAVANCE BIOPHARMA INC 0,45 % | 15/06/2026 | 232.457 ( 0,45 % ) | 4 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Director Técnico/Científico/I+D | - |
| Empresas | Cargo | Fin |
|---|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/08/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
University of Georgia
University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theravance Biopharma, Inc.
Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.